novalgen.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | NovalGen – Breakthrough bispecific antibody therapies to treat |
| Description | Clinical stage immuno-oncology company developing breakthrough bispecific antibodies to fight NovalGen is an innovative immuno-oncology company focused on bispecific antibody approaches to fight |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 104.47.160.14 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
novalgen.com Valuation
|
US$1,592
Last updated: 2023-05-20 05:32:54
novalgen.com has Semrush global rank of 0. novalgen.com has an estimated worth of US$ 1,592, based on its estimated Ads revenue. novalgen.com receives approximately 183 unique visitors each day. Its web server is located in United States, with IP address 104.47.160.14. According to SiteAdvisor, novalgen.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,592 |
| Daily Ads Revenue | US$1 |
| Monthly Ads Revenue | US$44 |
| Yearly Ads Revenue | US$529 |
| Daily Unique Visitors | 12 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| novalgen.com. | A | 599 | IP: 104.47.160.14 |
| novalgen.com. | NS | 3600 | NS Record: ns48.domaincontrol.com. |
| novalgen.com. | NS | 3600 | NS Record: ns47.domaincontrol.com. |
| novalgen.com. | MX | 3600 | MX Record: 1 novalgen-com.mail.protection.outlook.com. |
| novalgen.com. | TXT | 3600 | TXT Record: f1vr5mlzvpdk43xhhbcls5nwlnzb97h8 |
| novalgen.com. | TXT | 3600 | TXT Record: MS=ms61908763 |
| novalgen.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
HtmlToTextCheckTime:2023-05-20 05:32:54
| Jump to navigation (n) Jump to content Sitemap About us Back Overview Our mission Our team Our history Our investors Our values Community support Social responsibility Partnership & collaborations Our technologies Back Overview Our antibodies Auto-regulation platform Key capabilities Patients & families Back Overview Treatments Patient organisations Clinical trials About disease areas Pipeline News & publications Back Overview News Publications Careers Back Overview Vacancies Contact Menu Search Clinical stage immuno-oncology company developing breakthrough bispecific antibodies to fight cancer Explore Developing a first-in-class autoregulation technology to create safer drugs About us NovalGen’s first pipeline product is a proprietary first in class bispecific T cell engager therapies that can safely harness the immune system to fight a wide range of cancers. Our strategy Our technologies We are changing the paradigm of cancer therapy with our immunotherapy technology. Our focus is |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 148 Content-Type: text/html; charset=utf-8 Date: Fri, 13 Jan 2023 09:00:07 GMT Server: Microsoft-IIS/10.0 Location: https://www.novalgen.com/ X-Powered-By: ASP.NET HTTP/2 404 date: Fri, 13 Jan 2023 09:00:07 GMT content-length: 0 x-ua-compatible: IE=edge,chrome=1 referrer-policy: strict-origin feature-policy: ambient-light-sensor 'none'; autoplay 'self'; accelerometer 'none'; camera 'none'; document-domain 'self'; encrypted-media 'none'; fullscreen 'none'; geolocation '*'; microphone '*'; midi 'none'; payment 'none'; vr 'none x-content-type-options: nosniff x-xss-protection: 1; mode=block x-frame-options: ALLOW-FORM https://my.yano.digital strict-transport-security: max-age=31536000; preload content-security-policy: default-src *; img-src * 'self' data: https: blob:; script-src 'self' 'unsafe-inline' 'unsafe-eval' *; style-src 'self' 'unsafe-inline' *; font-src * 'self' data:; worker-src 'self' blob:; child-src blob:; frame-src *; frame-ancestors 'self' https://my.yano.digital |